EPHX2 and essential hypertension: However, based on previous evidence for blood pressure independent organ protective actions with sEH inhibitor administration in SHR [43], we cannot exclude that SHR, a model of essential hypertension, or other hypertensive rat models with a different genetic background could be less sensitive to anti-hypertensive EET-based therapy than that consistently observed in angiotensin II-dependent hypertension [16,19,33,44].